|
1
|
Fernandez SV, Robertson FM, Pei J,
Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z,
Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S and
Cristofanilli M: Inflammatory breast cancer (IBC): clues for
targeted therapies. Breast Cancer Res Treat. 140:23–33. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yasumura K, Ogawa K, Ishikawa H, Takeshita
T, Nakagawa Y and Osamura RY: Inflammatory carcinoma of the breast:
characteristic findings of MR imaging. Breast Cancer. 4:161–169.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamauchi H, Woodward WA, Valero V, Alvarez
RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W,
Reuben JM, Hortobágyi GN and Ueno NT: Inflammatory breast cancer:
what we know and what we need to learn. Oncologist. 17:891–899.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liedtke C, Bernemann C, Kiesel L and Rody
A: Genomic profiling in triple-negative breast cancer. Breast Care
(Basel). 8:408–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qiu M, Peng Q, Jiang I, Carroll C, Han G,
Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, Thibault
S, Stone D, Gao Y, Sofia S, Gallo J, Li G, Yang J, Li K and Wei P:
Specific inhibition of Notch1 signaling enhances the antitumor
efficacy of chemotherapy in triple negative breast cancer through
reduction of cancer stem cells. Cancer Lett. 328:261–270. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts
J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh
J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara
R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R,
Ditsch N, Rastogi P, Eiermann W and von Minckwitz G: Pathological
complete response and long-term clinical benefit in breast cancer:
the CTNeoBC pooled analysis. Lancet. Feb 14–2014.(Epub ahead of
print).
|
|
7
|
Crown J, O’Shaughnessy J and Gullo G:
Emerging targeted therapies in triple-negative breast cancer. Ann
Oncol. 23(Suppl 6): vi56–vi65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greenup R, Buchanan A, Lorizio W, Rhoads
K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P
and Shelley Hwang E: Prevalence of BRCA mutations among women with
triple-negative breast cancer (TNBC) in a genetic counseling
cohort. Ann Surg Oncol. 20:3254–3258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Venkitaraman AR: Cancer susceptibility and
the functions of BRCA1 and BRCA2. Cell. 108:171–182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farrugia DJ, Agarwal MK, Pankratz VS,
Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J,
Tavtigian SV, Goldgar DE and Couch FJ: Functional assays for
classification of BRCA2 variants of uncertain significance. Cancer
Res. 68:3523–3531. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kais Z, Chiba N, Ishioka C and Parvin JD:
Functional differences among BRCA1 missense mutations in the
control of centrosome duplication. Oncogene. 31:799–804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kolupaeva V and Basilico C: Overexpression
of cyclin E/CDK2 complexes overcomes FGF-induced cell cycle arrest
in the presence of hypophosphorylated Rb proteins. Cell Cycle.
11:2557–2566. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reed SI: Control of the G1/S transition.
Cancer Surv. 29:7–23. 1997.
|
|
14
|
D’Assoro AB, Lingle WL and Salisbury JL:
Centrosome amplification and the development of cancer. Oncogene.
21:6146–6153. 2002.
|
|
15
|
D’Assoro AB, Busby R, Suino K, Delva E,
Almodovar- Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V,
Stivala F and Salisbury JL: Genotoxic stress leads to centrosome
amplification in breast cancer cell lines that have an inactive
G1/S cell cycle checkpoint. Oncogene. 23:4068–4075. 2004.PubMed/NCBI
|
|
16
|
Hanashiro K, Kanai M, Geng Y, Sicinski P
and Fukasawa K: Roles of cyclins A and E in induction of centrosome
amplification in p53-compromised cells. Oncogene. 27:5288–5302.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell
LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial
mesenchymal transition generates cells with properties of stem
cells. Cell. 133:704–715. 2008. View Article : Google Scholar
|
|
18
|
Hwang-Verslues WW, Kuo WH, Chang PH, Pan
CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY,
Chang KJ and Lee WH: Multiple lineages of human breast cancer
stem/progenitor cells identified by profiling with stem cell
markers. PLoS One. 4:83772009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shipitsin M, Campbell LL, Argani P,
Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T,
Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker
LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ,
Nikolsky Y, Gelman RS and Polyak K: Molecular definition of breast
tumor heterogeneity. Cancer Cell. 11:259–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
D’Assoro AB, Liu T, Quatraro C, Amato A,
Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V,
Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A,
Billadeau D, McCubrey J, Ingle J, Salisbury JL and Galanis E: The
mitotic kinase Aurora-A promotes distant metastases by inducing
epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
Oncogene. 33:599–610. 2014.PubMed/NCBI
|
|
21
|
Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW,
Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS and Park SY: An
increase in cancer stem cell population after primary systemic
therapy is a poor prognostic factor in breast cancer. Br J Cancer.
104:1730–1738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arima Y, Hayashi N, Hayashi H, Sasaki M,
Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S and Saya
H: Loss of p16 expression is associated with the stem cell
characteristics of surface markers and therapeutic resistance in
estrogen receptor-negative breast cancer. Int J Cancer.
130:2568–2579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prat A, Karginova O, Parker JS, Fan C, He
X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M and Perou CM:
Characterization of cell lines derived from breast cancers and
normal mammary tissues for the study of the intrinsic molecular
subtypes. Breast Cancer Res Treat. 142:237–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D’Assoro AB, Leontovich A, Amato A,
Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle
J, Stivala F, Galanis E and Salisbury JL: Abrogation of p53
function leads to metastatic transcriptome networks that typify
tumor progression in human breast cancer xenografts. Int J Oncol.
37:1167–1176. 2010.PubMed/NCBI
|
|
25
|
D’Assoro AB, Barrett SL, Folk C, Negron
VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL and
Salisbury JL: Amplified centrosomes in breast cancer: a potential
indicator of tumor aggressiveness. Breast Cancer Res Treat.
75:25–34. 2002.PubMed/NCBI
|
|
26
|
Iovino F, Lentini L, Amato A and Di
Leonardo A: RB acute loss induces centrosome amplification and
aneuploidy in murine primary fibroblasts. Mol Cancer. 5:382006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mayer IA, Abramson VG, Lehmann BD and
Pietenpol JA: New strategies for triple-negative breast cancer -
deciphering the heterogeneity. Clin Cancer Res. 20:782–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mehta RS: Dose-dense and/or metronomic
schedules of specific chemotherapies consolidate the
chemosensitivity of triple-negative breast cancer: a step toward
reversing triple-negative paradox. J Clin Oncol. 26:3286–3288.
2008. View Article : Google Scholar
|
|
29
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to
neoadjuvant therapy and long-term survival in patients with
triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cristofanilli M, Buzdar AU, Sneige N,
Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero
V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C
and Hortobagyi GN: Paclitaxel in the multimodality treatment for
inflammatory breast carcinoma. Cancer. 92:1775–1782. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takahashi T, Akashi-Tanaka S, Fukutomi T,
Watanabe T, Katsumata N, Miyakawa K, Hasegawa T and Tsuda H: Two
special types of breast cancer presenting as progressive disease
after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Breast Cancer. 8:234–237. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leopold PL, Vincent J and Wang H: A
comparison of epithelial-to-mesenchymal transition and
re-epithelialization. Semin Cancer Biol. 22:471–483. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rosen EM and Pishvaian MJ: Targeting the
BRCA1/2 tumor suppressors. Curr Drug Targets. 15:17–31. 2014.
View Article : Google Scholar
|
|
34
|
Khoury-Haddad H, Guttmann-Raviv N,
Ipenberg I, Huggins D, Jeyasekharan AD and Ayoub N: PARP1-dependent
recruitment of KDM4D histone demethylase to DNA damage sites
promotes double-strand break repair. Proc Natl Acad Sci USA.
111:E728–E737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Węsierska-Gądek J, Zulehner N, Ferk F,
Składanowski A, Komina O and Maurer M: PARP inhibition potentiates
the cytotoxic activity of C-1305, a selective inhibitor of
topoisomerase II, in human BRCA1-positive breast cancer cells.
Biochem Pharmacol. 84:1318–1331. 2012.PubMed/NCBI
|
|
36
|
Shen Y, Rehman FL, Feng Y, Boshuizen J,
Bajrami I, Elliott R, Wang B, Lord CJ, Post LE and Ashworth A: BMN
673, a novel and highly potent PARP1/2 inhibitor for the treatment
of human cancers with DNA repair deficiency. Clin Cancer Res.
19:5003–5015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fojo T and Bates S: Mechanisms of
resistance to PARP inhibitors - three and counting. Cancer Discov.
3:20–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yin S, Xu L, Bandyopadhyay S, Sethi S and
Reddy KB: Cisplatin and TRAIL enhance breast cancer stem cell
death. Int J Oncol. 39:891–898. 2011.PubMed/NCBI
|
|
39
|
Potemski P, Kusińska R, Pasz-Walczak G,
Piekarski JH, Watała C, Płuciennik E, Bednarek AK and Kordek R:
Prognostic relevance of cyclin E expression in operable breast
cancer. Med Sci Monit. 15:MT34–MT40. 2009.PubMed/NCBI
|
|
40
|
Willmarth NE, Albertson DG and Ethier SP:
Chromosomal instability and lack of cyclin E regulation in hCdc4
mutant human breast cancer cells. Breast Cancer Res. 6:R531–R539.
2004. View
Article : Google Scholar : PubMed/NCBI
|
